drugset / Trial / NCT03300050
Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine
Phase 1
Completed
65 enrolled
PATH
Children's Hospital Medical Center, Cincinnati · collabDuke University · collabGlaxoSmithKline · collabIcahn School of Medicine at Mount Sinai · collabThe Emmes Company, LLC · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
The clinical study will evaluate safety and the immune response of a prime- boost regimen with a live attenuated influenza vaccine (LAIV) prime and an inactivated split influenza vaccine (IIV) boost with or without adjuvant.
Timeline
- Start
- 2017-10-10
- Primary completion
- 2018-04-24
- Completion
- 2019-08-09
Publications
- Meade P, Strohmeier S, Bermudez-Gonzalez MC, Garcia-Sastre A, Palese P, Simon V, Krammer F. Antigenic Landscape Analysis of Individuals Vaccinated with a Universal Influenza Virus Vaccine Candidate Reveals Induction of Cross-Subtype Immunity. J Virol. 2023 Jan 31;97(1):e0107022. doi: 10.1128/jvi.01070-22. Epub 2022 Dec 19.
- Nachbagauer R, Feser J, Naficy A, Bernstein DI, Guptill J, Walter EB, Berlanda-Scorza F, Stadlbauer D, Wilson PC, Aydillo T, Behzadi MA, Bhavsar D, Bliss C, Capuano C, Carreno JM, Chromikova V, Claeys C, Coughlan L, Freyn AW, Gast C, Javier A, Jiang K, Mariottini C, McMahon M, McNeal M, Solorzano A, Strohmeier S, Sun W, Van der Wielen M, Innis BL, Garcia-Sastre A, Palese P, Krammer F. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat Med. 2021 Jan;27(1):106-114. doi: 10.1038/s41591-020-1118-7. Epub 2020 Dec 7.
- Bernstein DI, Guptill J, Naficy A, Nachbagauer R, Berlanda-Scorza F, Feser J, Wilson PC, Solorzano A, Van der Wielen M, Walter EB, Albrecht RA, Buschle KN, Chen YQ, Claeys C, Dickey M, Dugan HL, Ermler ME, Freeman D, Gao M, Gast C, Guthmiller JJ, Hai R, Henry C, Lan LY, McNeal M, Palm AE, Shaw DG, Stamper CT, Sun W, Sutton V, Tepora ME, Wahid R, Wenzel H, Wohlbold TJ, Innis BL, Garcia-Sastre A, Palese P, Krammer F. Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial. Lancet Infect Dis. 2020 Jan;20(1):80-91. doi: 10.1016/S1473-3099(19)30393-7. Epub 2019 Oct 17.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AS03-adjuvanted cH5/1N1 IIV | Vaccine | 15 ug | Intramuscular |
| Subject | AS03-adjuvanted cH5/1N1 IIV | Vaccine | 0.5 ml | Intramuscular |
| Subject | AS03-adjuvanted cH8/1N1 IIV | Vaccine | 15 ug | Intramuscular |
| Subject | AS03-adjuvanted cH8/1N1 IIV | Vaccine | 0.5 ml | Intramuscular |
| Subject | cH5/1N1 IIV | Vaccine | 15 ug | Intramuscular |
| Subject | cH5/1N1 IIV | Vaccine | 0.5 ml | Intramuscular |
| Subject | cH8/1N1 LAIV | Vaccine | 0.5 ml | Intranasal |
| Subject | cH8/1N1 LAIV | Vaccine | 3.16228e+07 unknown | Intranasal |